#United States #Francis Medical #Vanquish #Maple Grove #VAPOR 2

Francis Medical’s Groundbreaking VAPOR 2 Trial Results Published

Francis Medical, Inc., a pioneer in the development of minimally invasive treatments for urological cancers, has recently shared encouraging findings from their VAPOR 2 pivotal clinical study, published in The Journal of Urology. This research represents a significant advancement in the management of localized prostate cancer, highlighting the effectiveness and safety of the Vanquish® Water Vapor Ablation System.

The VAPOR 2 study enrolled 235 patients across 26 clinical sites in the United States, including the initial report from the first 110 participants. The results indicate that 91% of patients achieved clearance of MRI-visible Grade Group 2 or greater disease after just one treatment. Importantly, there were no serious device-related adverse events, with low incidences of urinary incontinence and erectile dysfunction reported.

Key Findings

• - High Efficacy: The study revealed a remarkable 91% success rate in clearing targeted lesions in the prostate, showcasing the procedure's potential as an effective treatment option.
• - Safety Profile: The absence of serious adverse events coupled with low rates of complications provides strong evidence for the systemic safety of the therapy.
• - Patient Satisfaction: Notably, 93% of patients expressed satisfaction with their treatment experience, suggesting that Vanquish therapy not only benefits their health but also their quality of life.
• - Comprehensive Treatment Capability: The findings showcased the ability of the Vanquish system to effectively treat lesions located in challenging anatomical areas, which often limit other therapies.

What is the Vanquish® System?

The Vanquish system is a minimally invasive, transurethral procedure designed to ablate targeted prostate tissue utilizing convective thermal water vapor energy. The technology works by delivering sterile water vapor directly into the prostate tissue. As the vapor condenses, it releases thermal energy that causes cellular necrosis while remaining confined to the intended treatment area, preserving surrounding structures crucial for urinary continence and erectile function. This innovative approach distinguishes Vanquish from traditional treatments, emphasizing the demand for effective yet gentle oncological therapies.

Expert Commentary

Mike Kujak, President and CEO of Francis Medical, expressed his enthusiasm regarding the publication of the VAPOR 2 trial results, stating, "This marks a significant milestone for Francis Medical and the field of focal therapy. The initial results support the potential of water vapor ablation as a safe and effective option for prostate cancer treatment, while also preserving overall quality of life for patients."

Dr. Samir Taneja, co-principal investigator of the study, added, "The ability to target and ablate prostate tissue with minimal impact on surrounding structures is a game-changer for selected patients."

Future Directions

The VAPOR 2 study is ongoing, with patient follow-up extending to five years to gather further data on long-term outcomes. This research is aimed at bolstering evidence for a pre-market approval (PMA) submission to expand the indications for managing clinically localized prostate cancer.

The study's findings underscore the importance of continued innovation in urological oncology, as Francis Medical strives to shift the paradigm towards procedures that are effective, safe, and minimally invasive.

For more insights and access to the complete study, individuals can visit The Journal of Urology online.

About Francis Medical

Founded on the vision of delivering advanced cancer therapies that are tough on cancer yet gentle on patients, Francis Medical is committed to developing safe and effective solutions for urological cancers. Their dedication to providing high-quality clinical evidence is evident in their innovative approach to prostate cancer treatments. For more information, visit Francis Medical's website or call (763) 951-0370.